Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Senderowicz

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Urologia Internationalis|December 11, 1999
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancerA M Senderowicz, R Reid, D Headlee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cellsR W Robey, W Y Medina-Pérez, K Nishiyama, et al.
The Journal of Clinical Investigation|November 5, 1998
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosisV Patel, A M Senderowicz, D Pinto, et al.
Journal of the National Cancer Institute|January 4, 1995
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeletonA M Senderowicz, G Kaur, E Sainz, et al.
The Journal of Biological Chemistry|December 5, 1998
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphataseL Yu, L Orlandi, P Wang, et al.
Blood|January 15, 1998
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridolB W Parker, G Kaur, W Nieves-Neira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigmW H Wilson, L Sorbara, W D Figg, et al.
Cancer Chemotherapy and Pharmacology|September 28, 1998
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical modelsE A Sausville, R D Lush, D Headlee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasmsA M Senderowicz, D Headlee, S F Stinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancerN A Dawson, W D Figg, M R Cooper, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Urologia Internationalis|December 11, 1999
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancerA M Senderowicz, R Reid, D Headlee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cellsR W Robey, W Y Medina-Pérez, K Nishiyama, et al.
The Journal of Clinical Investigation|November 5, 1998
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosisV Patel, A M Senderowicz, D Pinto, et al.
Journal of the National Cancer Institute|January 4, 1995
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeletonA M Senderowicz, G Kaur, E Sainz, et al.
The Journal of Biological Chemistry|December 5, 1998
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphataseL Yu, L Orlandi, P Wang, et al.
Blood|January 15, 1998
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridolB W Parker, G Kaur, W Nieves-Neira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigmW H Wilson, L Sorbara, W D Figg, et al.
Cancer Chemotherapy and Pharmacology|September 28, 1998
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical modelsE A Sausville, R D Lush, D Headlee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasmsA M Senderowicz, D Headlee, S F Stinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancerN A Dawson, W D Figg, M R Cooper, et al.
Pageof 4